Clinical trial

Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression

NCT00518479

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2003-09-01

PhaseNA

Study timeline

Study start (unknown)2003-09-01Date precision: month

Registry last updated2012-08-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Hypertensionunresolved

Left Ventricular Hypertrophyunresolved

Interventions

Bendroflumethiazide 2.5mg OD; Amlodipine 10mg ODDRUG

Valsartan 160mg OD; Moxonidine 400mcg ODDRUG

Sponsors & collaborators

University of Leedslead sponsor

The Leeds Teaching Hospitals NHS Trustcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00518479 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.